-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4511 Early Identification of Very High Risk Patients with Diffuse Large B Cell Lymphoma (DLBCL) By PET-CT

Program: Oral and Poster Abstracts
Session: 627. Aggressive Lymphomas: Clinical and Epidemiological: Poster III
Hematology Disease Topics & Pathways:
Clinical Practice (Health Services and Quality), Non-Biological therapies, Chemotherapy, Therapies, Technology and Procedures, imaging
Monday, December 11, 2023, 6:00 PM-8:00 PM

Almudena Cabero Martínez1,2*, Luis Gonzaga Diaz Gonzalez2*, Carlos Montes2*, María Cortés-Rodríguez2*, Norma C. Gutierrez3*, Monica Baile Gonzalez4*, Ana García Bacelar4*, Miriam Lopez Parra1*, Jose Cristobal Cañadas4*, Juan Gabriel Villanueva4*, Francisco Javier Diaz Galvez5*, María Peñarrubia-Ponce6*, Silvia Maria Fernandez Ferrero7*, Jose Antonio Queizan Hernandez, MD8*, Miguel Cabezudo9*, Erik De Cabo López10*, Teresa Villaescusa11*, Pilar Tamayo4*, Ramon Garcia-Sanz4 and Alejandro Martin García-Sancho4*

1Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), Salamanca, Spain
2Hospital de Salamanca, Salamanca, Spain
3Hospital Universitario De Salamanca, Salamanca, ESP
4Hospital Universitario de Salamanca, Salamanca, Spain
5Hospital Universitario de Burgos, BURGOS, ESP
6Hospital ClíNico Universitario De Valladolid, Valladolid, ESP
7Hospital de León, Leon, ESP
8Hematology Department - Hospital General de Segovia, Segovia, Spain
9Hospital de Ávila, Ávila, Spain
10Hospital del Bierzo, Ponferrada, Spain
11Hospital de Zamora, Zamora, ESP


Early identification of very high risk patients with Diffuse Large B Cell Lymphoma (DLBCL) by PET-CT.


Early identification of high risk DLBCL after the start of treatment continues to be a challenge that has not been fully resolved. The main aim of this study was to analyze the prognostic impact on progression free survival (PFS) of some PET-CT parameters at diagnosis (PET0) and after two cycles of first-line treatment (PET2).


Patients diagnosed with DLBCL eligible for immunochemotherapy were prospectively included. A PET-CT was done at diagnosis, after two cycles of treatment and at the end of treatment. Metabolic tumoral volume (MTV), total lesion glycolysis (TLG) and maximum standardized uptake value (SUVmax) were the main initial parameters analyzed whereas Deauville score (Dv), the difference between PET0-PET2 SUVmax (deltaSUV) and MTV2 were the parameters analyzed after two cycles. The MTV was defined as the volume of hypermetabolic tissue with a SUV greater than a threshold value of 3 using volume viewer software (Lyfex). All PET/CT studies were performed at the same hospital and with the same equipment and analyzed by 3 Nuclear Medicine experts. The primary endpoint was PFS.


153 patients diagnosed with DLBCL from 8 hospitals in Castilla y León were included. All of them received first line treatment with R-CHOP or similar immunochemotherapy regimens. Median age was 64 (24-86) years, and 51% were male; 70% had III-IV Ann-Arbor stage. The revised International Prognostic Index (R-IPI) distribution was low risk (0), 7,2%, intermediate risk (1-2), 51%, and high risk (3-5), 41,8%. Median MTV0 was 478,6 cm3.

ROC analysis identified as the optimal cut-off points 700 cm3 for MTV0, 6430 cm3 for TLG0, 25 for SUVmax and 1,85 cm3 for MTV2. The cut-off of 66% was used for deltaSUV, as described in previous publications.

Overall response rate (ORR) after treatment was 87,6% (71,2% complete response). With a median follow up of 39 months, estimated PFS at 3 years was 74,8%.

In addition to R-IPI, all PET0 and PET2 parameters analyzed, with the exception of SUVmax at PET0, showed significant influence on PFS, as shown in table 1. In multivariate analysis, MTV0 and deltaSUV maintain independent influence. Based on these two factors, 3 groups with different PFS were obtained, as shown in figures 1, including a high-risk group (MTV0 >700 cm3 and deltaSUV <66%) that comprised 24% of the series, with PFS at 3 years of 30,5%.


The combination of different PET parameters at diagnosis and after two cycles of treatment give us the possibility of identify, independently of IPI, a subgroup of patients with very poor PFS. It could serve as a basis for risk-adapted treatments, although further prospective studies with larger population are required in order to confirm our results.

Disclosures: Lopez Parra: Janssen: Honoraria, Speakers Bureau; Novartis: Consultancy; Kite Gilead: Honoraria, Speakers Bureau; Celgene BMS: Consultancy. Garcia-Sanz: Janssen: Consultancy, Honoraria; Takeda: Consultancy, Honoraria. Martin García-Sancho: Roche: Consultancy; Janssen: Honoraria; Takeda: Consultancy; Novartis: Consultancy.

*signifies non-member of ASH